These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3863033)

  • 1. The economic costs to New Zealand of lost production due to alcohol abuse.
    Chetwynd J; Rayner T
    N Z Med J; 1985 Aug; 98(785):694-7. PubMed ID: 3863033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The social costs of alcohol abuse in New Zealand.
    Devlin NJ; Scuffham PA; Bunt LJ
    Addiction; 1997 Nov; 92(11):1491-505. PubMed ID: 9519492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of alcohol and drug abuse in the United States, 1992. Alcohol/Drugs COI Study Team.
    Holland P; Mushinski M
    Stat Bull Metrop Insur Co; 1999; 80(4):2-9. PubMed ID: 10553265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated cost of alcohol to the New Zealand public hospital system.
    Ashton T; Casswell S
    N Z Med J; 1984 Oct; 97(765):683-6. PubMed ID: 6592482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Income and employment of people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders.
    Conover CJ; Arno P; Weaver M; Ang A; Ettner SL
    J Ment Health Policy Econ; 2006 Jun; 9(2):71-86. PubMed ID: 17007485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injury risk among medically identified alcohol and drug abusers.
    Miller TR; Lestina DC; Smith GS
    Alcohol Clin Exp Res; 2001 Jan; 25(1):54-9. PubMed ID: 11198715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic cost of community-acquired pneumonia in New Zealand adults.
    Scott G; Scott H; Turley M; Baker M
    N Z Med J; 2004 Jun; 117(1196):U933. PubMed ID: 15280937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health promotion: Alcohol and drug misuse prevention.
    Public Health Rep; 1983; Suppl():116-32. PubMed ID: 6414012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Smoking-attributable productivity loss in Germany--a partial sickness cost study based on the human capital potential method].
    Wegner C; Gutsch A; Hessel F; Wasem J
    Gesundheitswesen; 2004 Jul; 66(7):423-32. PubMed ID: 15314734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
    Yeom HS; Shepard DS
    J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2003 Jun; 22(2):159-67. PubMed ID: 12850902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric illness among a nationally representative sample of sole and partnered parents in New Zealand.
    Tobias M; Gerritsen S; Kokaua J; Templeton R
    Aust N Z J Psychiatry; 2009 Feb; 43(2):136-44. PubMed ID: 19153921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of campylobacteriosis in New Zealand in 1995.
    Withington SG; Chambers ST
    N Z Med J; 1997 Jun; 110(1046):222-4. PubMed ID: 9236803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of nine common mental disorders: implications for curative and preventive psychiatry.
    Smit F; Cuijpers P; Oostenbrink J; Batelaan N; de Graaf R; Beekman A
    J Ment Health Policy Econ; 2006 Dec; 9(4):193-200. PubMed ID: 17200596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic cost to New Zealand of foodborne infectious disease.
    Scott WG; Scott HM; Lake RJ; Baker MG
    N Z Med J; 2000 Jul; 113(1113):281-4. PubMed ID: 10935568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the economic costs of the abuse of tobacco, alcohol and illicit drugs: a review of methodologies and Canadian data sources.
    Choi BC; Robson L; Single E
    Chronic Dis Can; 1997; 18(4):149-65. PubMed ID: 9445363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmet substance abuse treatment need, health services utilization, and cost: a population-based emergency department study.
    Rockett IR; Putnam SL; Jia H; Chang CF; Smith GS
    Ann Emerg Med; 2005 Feb; 45(2):118-27. PubMed ID: 15671966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS).
    Godfrey C; Stewart D; Gossop M
    Addiction; 2004 Jun; 99(6):697-707. PubMed ID: 15139868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onset and lifetime use of drugs in New Zealand: results from Te Rau Hinengaro: the New Zealand Mental Health Survey 2003-2004.
    Wells JE; McGee MA; Baxter J; Agnew F; Kokaua J;
    Drug Alcohol Rev; 2009 Mar; 28(2):166-74. PubMed ID: 19320702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.